Helin Vakifahmetoglu-Norberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3256063/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	The role of mitochondria in metabolism and cell death. Biochemical and Biophysical Research Communications, 2017, 482, 426-431.	2.1	462
3	Pharmacologic agents targeting autophagy. Journal of Clinical Investigation, 2015, 125, 5-13.	8.2	198
4	Chaperone-mediated autophagy degrades mutant p53. Genes and Development, 2013, 27, 1718-1730.	5.9	154
5	PHCDH Defines a Metabolic Subtype in Lung Adenocarcinomas with Poor Prognosis. Cell Reports, 2017, 19, 2289-2303.	6.4	118
6	The unpredictable caspase-2: what can it do?. Trends in Cell Biology, 2010, 20, 150-159.	7.9	102
7	Degradation of HK2 by chaperone-mediated autophagy promotes metabolic catastrophe and cell death. Journal of Cell Biology, 2015, 210, 705-716.	5.2	95
8	Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism. Molecular and Cellular Biology, 2017, 37, .	2.3	74
9	Targetome analysis of chaperone-mediated autophagy in cancer cells. Autophagy, 2019, 15, 1558-1571.	9.1	63
10	USP10 regulates the stability of the EMT-transcription factor Slug/SNAI2. Biochemical and Biophysical Research Communications, 2018, 502, 429-434.	2.1	34
11	Mutant p53 as a Regulator and Target of Autophagy. Frontiers in Oncology, 2020, 10, 607149.	2.8	32
12	Characterization of the Role of the Malate Dehydrogenases to Lung Tumor Cell Survival. Journal of Cancer, 2017, 8, 2088-2096.	2.5	31
13	miR-126-5p targets Malate Dehydrogenase 1 in non-small cell lung carcinomas. Biochemical and Biophysical Research Communications, 2018, 499, 314-320.	2.1	22
14	The deubiquitinase JOSD2 is a positive regulator of glucose metabolism. Cell Death and Differentiation, 2021, 28, 1091-1109.	11.2	20
15	miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC. Biochemical and Biophysical Research Communications, 2019, 511, 260-265.	2.1	19
16	Quantitative proteomic analysis of temporal lysosomal proteome and the impact of the KFERQ-like motif and LAMP2A in lysosomal targeting. Autophagy, 2021, 17, 3865-3874.	9.1	19
17	Activation of chaperone-mediated autophagy as a potential anticancer therapy. Autophagy, 2015, 11, 2370-2371.	9.1	18
18	Systematic analysis reveals a functional role for STAMBPL1 in the epithelial–mesenchymal transition process across multiple carcinomas. British Journal of Cancer, 2020, 123, 1164-1177	6.4	10

HELIN

#	Article	IF	CITATIONS
19	Resistant to Targeted Therapy - Aim for Metabolic Liabilities. Theranostics, 2018, 8, 2061-2063.	10.0	6
20	A degradative detour for mutant TP53. Autophagy, 2013, 9, 2158-2160.	9.1	5
21	CRISPR-Cas9 Gene Editing to Generate Isoform-Specific LAMP-2A Knockout in Human Cancer Cells. Methods in Molecular Biology, 2022, 2445, 39-50.	0.9	2
22	Small molecule "on―and "off―switches for autophagy. FASEB Journal, 2012, 26, 220.2.	0.5	0
23	Isolation of Autophagy Competent from Cancer Cells by Differential Large-Scale Multilayered Density Gradient Centrifugations. Methods in Molecular Biology, 2022, 2445, 27-38.	0.9	Ο